CENTOGENE And Evotec Announce Discovery Of New Molecule To Treat Gaucher Disease
CENTOGENE And Evotec Announce Discovery Of New Molecule To Treat Gaucher Disease
- CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical research
- Companies amend existing drug discovery partnership for Evotec to lead continued development. Upon Evotec exercising its option, CENTOGENE to receive an option exercise fee and other potential milestone payments and royalties
- CENTOGENE將獲得許可費，爲Evotec提供研發許可證，以完成下一階段的臨床前研究
- 各公司修改了Evotec現有的藥物研發合作伙伴關係，以領導持續發展。在Evotec行使期權後，CENTOGENE將獲得期權行使費和其他潛在的里程碑付款和特許權使用費
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 14, 2024 (GLOBE NEWSWIRE) --
馬薩諸塞州劍橋和德國羅斯托克以及柏林，2024 年 5 月 14 日（GLOBE NEWSWIRE）—
Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the discovery of a new small molecule together with Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO). The new molecule has the potential to treat patients with type 2 and type 3 Gaucher disease, otherwise known as neuronopathic Gaucher disease. The discovery has been the result of the collaborative work under the existing drug discovery partnership which has been in place since 2020.
Centogene N.V.（納斯達克股票代碼：CNTG）是罕見和神經退行性疾病數據驅動答案的重要生命科學合作伙伴，今天宣佈與Evotec SE（法蘭克福證券交易所：EVT，MDAX/TecDAX，場外交易代碼：EVOT，納斯達克股票代碼：EVO）一起發現了一種新的小分子。這種新分子有可能治療患有2型和3型高歇氏病（也稱爲神經元病變性高歇氏病）的患者。這一發現是自2020年以來建立的現有藥物研發夥伴關係下合作的結果。
譯文內容由第三人軟體翻譯。